ArticleJournal of health, population, and nutrition2026
Fasting blood glucose trajectories and atherosclerosis risk: a longitudinal cohort study with threshold analysis in Chongqing, China.
Article in Journal of health, population, and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAtherosclerosis, the primary pathological basis of cardiovascular diseases, exhibits a strong association with glucose metabolism dysregulation. While cross-sectional studies have linked fasting blood glucose (FBG) to atherosclerosis risk, the dose-response relationship and threshold characteristics of long-term FBG trajectories remain poorly characterized. This retrospective cohort study aimed to investigate longitudinal FBG trajectory patterns and their associations with atherosclerosis risk prevalence, incidence, and recovery in Chongqing, China, while also identifying population-specific risk thresholds.
methodsBased on the three-year longitudinal follow-up data collected annually from 2017 to 2019, a population-based trajectory model (GBTM) was adopted to identify the dynamic trajectory of FBG. The association between FBG and atherosclerosis risk was analyzed using multivariable logistic regression. Restricted cubic splines (RCS) were used to assess the non-linear relationship between FBG and atherosclerosis risk and to determine risk thresholds. Confounding factors such as age, sex, body mass index (BMI), blood pressure, and lipids were adjusted for in the regression models, and subgroup analyses were performed to examine the interactions of age, sex, and BMI.
resultsLongitudinal analysis showed that compared with the Trajectory Normal Glucose Regulation (NGR) group, the Trajectory Prediabetes Mellitus group (Pre-DM) group had significantly higher prevalence (OR: 2.02, 95% CI: 1.63-2.51) and incidence (OR: 1.66, 95% CI: 1.15-2.39) of atherosclerosis risk. The Trajectory Pre-DM group also had a significantly lower likelihood of atherosclerosis risk recovery than the Trajectory NGR group (OR: 0.55, 95% CI: 0.39-0.79). Dose-response analysis revealed a non-linear association between FBG and atherosclerosis risk prevalence, with a risk threshold at 5.10 mmol/L. This suggests that the atherosclerosis risk threshold in Chongqing is significantly lower than the international prediabetes standard of 5.60 mmol/L. Subgroup analyses showed sex and age differences, with lower thresholds in women and younger individuals.
conclusionsLong-term elevation of FBG was associated with increased atherosclerosis risk. The study suggests that intervention strategies should be based on dynamic blood glucose trajectories and population-specific thresholds, especially lower thresholds for women and younger individuals. This study provides evidence-based support for regional atherosclerosis risk prevention and control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.